Перед продажей нового препарата производитель практически никогда не тестирует продукт на беременных женщинах, чтобы определить влияние этого препарата на плод. Следовательно, большинство лекарств не назначают во время беременности. Как правило, описание лекарственного средства, указанного в «Справочнике врача» и аналогичных источниках, включает такие слова, как «Нельзя использовать во время беременности, не рекомендуется во время беременности, если только это не представляет опасности для плода». Поскольку риск достаточно определен только для нескольких лекарств, врачи, осуществляющие уход за беременными женщинами, имеют очень мало информации, чтобы помочь определить, перевешивают ли потенциальные преимущества для матери риски для плода. Хотя эти общие отказы понятны с точки зрения медицинского права, они трудны для многих женщин и их врачей по ряду причин.
Перед продажей нового препарата производитель практически никогда не тестирует продукт на беременных женщинах, чтобы определить влияние этого препарата на плод. Следовательно, большинство лекарств не назначают во время беременности. Как правило, описание лекарственного средства, указанного в «Справочнике врача» и аналогичных источниках, включает такие слова, как «Нельзя использовать во время беременности, не рекомендуется во время беременности, если только это не представляет опасности для плода». Поскольку риск достаточно определен только для нескольких лекарств, врачи, осуществляющие уход за беременными женщинами, имеют очень мало информации, чтобы помочь определить, перевешивают ли потенциальные преимущества для матери риски для плода. Хотя эти общие отказы понятны с точки зрения медицинского права, они трудны для многих женщин и их врачей по ряду причин.
Ishlab chiqarilgan yangi dori vositalarini sotishdan avval, ishlab chiqaruvchi ushbu preparatning homilaga ta'sirini aniqlash uchun homilador ayollarda mahsulotni deyarli hech qachon sinovdan o'tkazmaydi. Binobarin, ko'pchilik dorilar homiladorlik paytida foydalanish uchun belgilanmagan. Odatda, "Shifokorlarma'lumotnomasi"davashungao'xshashmanbalardakeltirilgandori-darmonlarning tavsifida "Homiladorlik paytida foydalanish mumkin emas, agar homila uchun xavf tug'dirmasa, homiladorlik paytida foydalanish tavsiya etilmaydi" kabi so'zlar mavjud. Xavf faqat bir nechta dorilar uchun yetarli darajada aniqlanganligi sababli, homilador ayollarga g'amxo'rlik qilayotgan shifokorlar onaning potentsial foydalari homila uchun xavfdan ustunligini aniqlashga yordam beradigan juda kam ma'lumotga ega. Ushbu odatiy rad etishlar tibbiy qonun nuqtai nazaridan tushunarli bo'lsa-da, ko'p sonli ayollar va ularning shifokorlariga bir necha sabablarga ko'ra qiyinchilik tug’diradi.
Before marketing a new drug, the manufacturer almost never tests the product in pregnant women to determine its effects on the fetus. Consequently, most drugs are not labeled for use during pregnancy. Typically, descriptions of drugs that appear in the Physicians' Desk Reference and similar sources contain statements such as, “Use in pregnancy is not recommended unless the potential benefits justify the potential risks to the fetus.” Since the risk has been adequately established for only a few drugs, physicians caring for pregnant women have very little information to help them decide whether the potential benefits to the mother outweigh the risks to the fetus. These typical disclaimers, although understandable from the medicolegal standpoint, put large numbers of women and their physicians in difficult situations for several reasons.
№ | Author name | position | Name of organisation |
---|---|---|---|
1 | Soatova N.E. | . | ASMI |
2 | Kodirova M.N. | . | ASMI |
3 | Isakov K.K. | . | ASMI |
№ | Name of reference |
---|---|
1 | 1. Andersen, J. T., &Futtrup, T. B. (2020). Drugs in pregnancy. Adverse Drug Reaction Bulletin, 321(1), 1243–1246. doi:10.1097/fad.0000000000000047. |
2 | 2. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015;105:140–156 |
3 | 3. McCallister JW. Asthma in pregnancy: management strategies. CurrOpinPulm Med 2013;19:13–17. |
4 | 4. Giden K, Andersen JT, Torp-Pedersen AL, et al. Use of thyroid hormones in relation to pregnancy: a Danish nationwide cohort study. ActaObstetGynecolScand 2015;94: 591–597. |
5 | 5. Thomseth V, Cejvanovic V, Jimenez-Solem E, et al. Exposure to topical chloramphenicol during pregnancy and the risk of congenital malformations: a Danish nationwide cohort study. ActaOphthalmol 2015;93: 6513. |
6 | 6. Andersen J, Rasmussen J, Glintborg B, et al. Changes in antibiotic prescription in pregnancy are not explained by present guidelines. Pharmacoepidemiol. Drug Saf 2008; 17:S160. |
7 | 7. Nordeng H. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J ClinPharmacol 2010;66:207–214. |
8 | 8. Eck LK, Jensen TB, Mastrogiannis D, et al. Risk of adverse pregnancy outcome after paternal exposure to methotrexate within 90 days before pregnancy. ObstetGynecol 2017;129:707–714. |
9 | 9. Khiali S, Gharekhani A, Entezari-Maleki T. Isotretinoin; A review on the Utilization Pattern in Pregnancy. Adv Pharm Bull 2018;8:377–382 |
10 | 10. Schardein JL. Chemically induced birth defects, third edition. Chapter one: principles of teratogenesis applicable to drug and chemical exposure. New York: Marcel Dekker, Inc; 2000. |
11 | 11. Bergman TF, Andersen JT. Common pharmacological issues in pregnancy. RationelFarmakoterapi 2019;6:1–5. |
12 | 12. Koren, G., Pastuszak, A., & Ito, S. (1998). Drugs in Pregnancy. New England Journal of Medicine, 338(16), 1128–1137. doi:10.1056/nejm199804163381607. |
13 | 13. Loebstein R, Lalkin A, Koren G. Pregnancy induced pharmacokinetic changes and their clinical relevance. ClinPharmacokinet 1997;33:328-43. |
14 | 14. Theis JGW. Acetylsalicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy: are they safe? Can Fam Physician 1996;42:2347-9. |
15 | 15. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf 2014;13:1569–1581. |
16 | 16. Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation? Expert Opin Drug Saf 2016;15:367–382. |
17 | 17. Eck LK, Jensen TB, Mastrogiannis D, et al. Risk of adverse pregnancy outcome after paternal exposure to methotrexate within 90 days before pregnancy. ObstetGynecol 2017;129:707–714 |
18 | 18. Haastrup MB. Analgetics in pregnancy.Ma˚nedsbladetRationelFarmakoterapi 2016;5:1–2. |
19 | 19. Hyperemesis gravidarum - guideline - DSOG. 2013. http://gynobsguideline.dk/ sandbjerg/Hyperemesisgravidarum.pdf (16 Aug 2016). |
20 | 20. Namazy JA, Schatz M. Management of asthma during pregnancy: optimizing outcomes and minimizing risk. SeminRespirCrit Care Med 2018;39:29–35. |
21 | 21. Andersson NW, Poulsen HE, Andersen JT. Desloratadine use during pregnancy and risk of adverse fetal outcomes: a nationwide cohort study. J Allergy ClinImmunolPract 2020 |
22 | 22. Poulsen BK, Krag MØ. Treatment of allergy in pregnancy.Ma˚nedsbladetRationelFarmakoterapi 2017;6:3–4. |
23 | 23. Ka¨llen BA, Olausson PO. Use of oral decongestants during pregnancy and delivery outcome. Am J ObstetGynecol 2006;194:480– 485 |
24 | 24. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J ClinEndocrinolMetab 2012;97:2543–2565. |
25 | 25. Mølgaard-Nielsen D, Svanstr€om H, Melbye M, et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016;315:58–67. |
26 | 26. Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013;369:830–839. |
27 | 27. Bergman TF, Andersen JT. Common pharmacological issues in pregnancy. RationelFarmakoterapi 2019;6:1–5. |
28 | 28. Larsen ER, Damkier P, Pedersen LH, et al., Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding.ActaPsychiatrScandSuppl 2015:1–28. |
29 | 29. Cuomo A, Maina G, Neal SM, et al. Using sertraline in postpartum and breastfeeding: balancing risks and benefits. Expert Opin Drug Saf 2018;17:719–725 |
30 | 30. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:. e001148. |
31 | 31. Pasternak B, Hviid A. Use of protonpump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010;363:2114– 2123. |
32 | 32. Vazquez JC. Constipation, haemorrhoids, and heartburn in pregnancy. BMJ ClinEvid 2008;2008:1411 |
33 | 33. Body C, Christie JA. gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. GastroenterolClin North Am 2016;45:267–283. |